STOCK TITAN

Alnylam Pharmaceuticals, Inc. - ALNY STOCK NEWS

Welcome to our dedicated page for Alnylam Pharmaceuticals news (Ticker: ALNY), a resource for investors and traders seeking the latest updates and insights on Alnylam Pharmaceuticals stock.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) is at the forefront of RNA interference (RNAi) therapeutics, pioneering a transformative class of medicines aimed at treating and potentially curing a wide range of diseases. Founded in 2002 and based in Cambridge, MA, Alnylam has translated Nobel Prize-winning science into five commercial products: ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran), and Leqvio (inclisiran), developed and commercialized in partnership with Novartis. These breakthrough therapeutics address conditions such as hATTR amyloidosis, acute hepatic porphyria, primary hyperoxaluria type 1, and hypercholesterolemia.

Alnylam is dedicated to expanding its pipeline with several investigational medicines in late-stage development, focusing on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases. The company’s commitment to sustainable innovation is reflected in its robust product pipeline and strategic collaborations with industry leaders like Roche and Regeneron.

Financially, Alnylam reported robust growth in 2023 with $1.24 billion in global net product revenues, a reflection of its strong commercial execution across its therapeutic products. The company maintains a strong cash position, bolstered by upfront fees from research partnerships and milestone achievements.

Alnylam is also dedicated to corporate responsibility, with initiatives aimed at reducing greenhouse gas emissions, promoting diversity and inclusion in clinical trials, and expanding global health equity through its Alnylam Challengers program. The company’s environmental impact data is third-party verified, underscoring its commitment to transparency and sustainability.

Looking ahead, Alnylam aims to sustain its leadership in RNAi therapeutics with the anticipated release of topline results from the HELIOS-B Phase 3 study and the continued development of promising candidates like zilebesiran for hypertension and mivelsiran for Alzheimer’s disease. For more details on Alnylam’s people, science, and pipeline, visit www.alnylam.com.

Rhea-AI Summary

Alnylam Pharmaceuticals (Nasdaq: ALNY), a leader in RNAi therapeutics, has announced its plan to report second quarter 2024 financial results on Thursday, August 1, 2024, before U.S. markets open. The company will host a conference call at 8:30 am ET on the same day, where management will provide a company update and discuss Q2 2024 results along with future expectations.

Investors can access a live audio webcast of the call on Alnylam's website in the Investors section. An archived version of the webcast will be available approximately two hours after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
conferences earnings
-
Rhea-AI Summary

Alnylam Pharmaceuticals reported positive topline results from its HELIOS-B Phase 3 study for vutrisiran, an RNAi therapeutic for ATTR amyloidosis with cardiomyopathy (ATTR-CM).

Statistically significant reductions in all-cause mortality and recurrent cardiovascular events were observed in both the overall population and monotherapy population. Specifically, the study showed a 28% reduction in the overall population and a 33% reduction in the monotherapy population.

Secondary endpoints also demonstrated significant improvements, including a 36% reduction in all-cause mortality in the overall population and a 35% reduction in the monotherapy population. Other key measures such as the 6-minute walk test, Kansas City Cardiomyopathy Questionnaire, and NYHA Class also showed clinical benefits.

The study confirmed vutrisiran's safety profile, with adverse events comparable between the vutrisiran and placebo groups. Alnylam plans to file a U.S. Supplemental New Drug Application and proceed with global regulatory submissions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
34.52%
Tags
-
Rhea-AI Summary

Alnylam Pharmaceuticals, Inc. issued its 2023 Corporate Responsibility Report, showcasing its commitment to environmental sustainability, patient access, and health equity. The report includes new data on environmental impact, expanded partnerships for diversity and inclusion in clinical trials, and the extension of the Alnylam Challengers global health equity initiative. Additionally, the report discloses employee demographic data and results of a pay equity analysis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
none
Rhea-AI Summary

Alnylam Pharmaceuticals reported strong first quarter 2024 financial results with Global Net Product Revenues of $365 million, reflecting a 32% Year-Over-Year Growth. The company achieved positive results in the Zilebesiran Hypertension Program, initiated Phase 2 studies, and remains on track to report Topline Results from Vutrisiran's Phase 3 Study. Alnylam reiterated its 2024 Financial Guidance with expected combined Net Product Revenues of $1,400 million to $1,500 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
-
Rhea-AI Summary

Medison Pharma and Alnylam Pharmaceuticals have announced an expansion of their partnership to commercialize RNAi therapeutics in additional markets, including LATAM and APAC, to provide innovative therapies to patients across the globe. This partnership aims to accelerate access to Alnylam's life-saving therapies in multiple regions under one global alliance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
partnership
-
Rhea-AI Summary
Alnylam Pharmaceuticals, Inc. (ALNY) will announce its first quarter 2024 financial results on May 2, 2024. The company will discuss its performance and future outlook via a conference call at 8:30 am ET. Participants can register online to access the call and a replay will be available afterward. A live webcast will be accessible on the Investors section of the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
conferences earnings
Rhea-AI Summary
Alnylam Pharmaceuticals, Inc. announces positive results from the KARDIA-2 Phase 2 study evaluating zilebesiran for hypertension treatment. The study showed significant reductions in blood pressure across three independent cohorts, with encouraging safety profiles. Zilebesiran aims to address treatment gaps in hypertension management and offers the potential for biannual dosing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Alnylam Pharmaceuticals, Inc. will discuss results from the KARDIA-2 Phase 2 study of zilebesiran, an RNAi therapeutic for hypertension, at the ACC Scientific Session. The webcast event will feature presentations and a Q&A session with Alnylam management and Dr. Akshay Desai.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
conferences clinical trial
-
Rhea-AI Summary
Alnylam Pharmaceuticals Launches Family Health History Road Trip Program to Encourage Health Conversations
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
none
Rhea-AI Summary
ByHeart, a next-generation baby nutrition company, appoints Amy Schulman as Chair of the Board, signaling a significant milestone for the company. Schulman, with extensive experience in infant formula and consumer health from Pfizer, brings valuable insights and expertise to ByHeart's leadership team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
management

FAQ

What is Alnylam Pharmaceuticals known for?

Alnylam Pharmaceuticals is known for pioneering RNA interference (RNAi) therapeutics, which are innovative medicines designed to silence disease-causing genes.

What products has Alnylam commercialized?

Alnylam has commercialized ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran), and Leqvio (inclisiran).

What diseases do Alnylam’s products treat?

Alnylam’s products treat conditions like hATTR amyloidosis, acute hepatic porphyria, primary hyperoxaluria type 1, and hypercholesterolemia.

What are the recent financial achievements of Alnylam?

In 2023, Alnylam reported $1.24 billion in global net product revenues, reflecting strong commercial execution and growth.

Who are Alnylam’s key strategic partners?

Key strategic partners include Roche, Regeneron, and Novartis, with collaborations focusing on various clinical programs and commercial products.

What environmental initiatives has Alnylam undertaken?

Alnylam has disclosed multiyear data on greenhouse gas emissions, energy, water, and waste management, with third-party verification to ensure transparency and sustainability.

What is the Alnylam Challengers program?

The Alnylam Challengers program is a global health equity initiative that partners with social entrepreneurs and non-profit organizations to address health and economic inequalities.

What are some key pipeline developments for Alnylam?

Key pipeline developments include the HELIOS-B Phase 3 study for vutrisiran in ATTR amyloidosis, and early-stage developments for mivelsiran in Alzheimer’s disease.

Where is Alnylam Pharmaceuticals headquartered?

Alnylam Pharmaceuticals is headquartered in Cambridge, Massachusetts.

How can I learn more about Alnylam Pharmaceuticals?

For more information, visit their official website at www.alnylam.com.

Alnylam Pharmaceuticals, Inc.

Nasdaq:ALNY

ALNY Rankings

ALNY Stock Data

30.01B
126.49M
0.42%
92.72%
1.68%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE